Acurx Pharmaceuticals, Inc.
NASDAQ:ACXP
0.3543 (USD) • At close April 11, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 5,403.836 | 6.044 | 4.754 | 2.03 | 2.203 | 3.51 |
| General & Administrative Expenses
| 8,699.267 | 8.534 | 7.339 | 10.784 | 2.397 | 2.421 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8,699.267 | 8.534 | 7.339 | 10.784 | 2.397 | 2.421 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 14,103.103 | 14.578 | 12.093 | 12.814 | 4.6 | 5.931 |
| Operating Income
| 0 | -14.578 | -12.094 | -12.881 | -4.6 | -5.931 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0 | 0 | -0 | 0.067 | 0 | 0 |
| Income Before Tax
| -14,103.103 | -14.578 | -12.093 | -12.748 | -4.6 | -5.931 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.001 | -0.067 | -0.005 | -0.006 |
| Net Income
| -14,103.103 | -14.578 | -12.092 | -12.681 | -4.6 | -5.931 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -872.54 | -1.15 | -1.12 | -1.24 | -0.46 | -0.6 |
| EPS Diluted
| -872.54 | -1.15 | -1.12 | -1.24 | -0.46 | -0.6 |
| EBITDA
| 0 | 0 | -12.093 | 0 | -4.6 | -5.931 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |